Muirhead M R, Somogyi A A, Rolan P E, Bochner F
Clin Pharmacol Ther. 1986 Oct;40(4):400-7. doi: 10.1038/clpt.1986.197.
A chronic-dosing pharmacokinetic study was carried out in six healthy subjects to examine the potential for cimetidine to reduce the CLR and CLH of triamterene. Blood and urine samples were collected frequently for 24 hours after dosing with triamterene alone (100 mg/day) for 4 days and concomitant cimetidine (400 mg twice daily) for an additional 4 days. Cimetidine significantly reduced the clearance of triamterene by hydroxylation by 32% (P less than 0.016) and the CLR of triamterene by 28% (P less than 0.063), with no change in its protein binding. The CLR of the active sulfate conjugate of triamterene was not altered by cimetidine. There was a reduced recovery of triamterene and its metabolites in urine after cimetidine, suggesting a decreased absorption. These results are consistent with cimetidine inhibiting cytochrome P-450 enzymes in the liver and also competing with triamterene for renal tubular secretion. Despite the pharmacokinetic interaction, cimetidine caused minimal alteration to the natriuretic and antikaliuretic effects of triamterene.
在6名健康受试者中进行了一项长期给药的药代动力学研究,以考察西咪替丁降低氨苯蝶啶肝脏清除率(CLH)和肾脏清除率(CLR)的可能性。在单独给予氨苯蝶啶(100mg/天)4天,随后再联合给予西咪替丁(400mg,每日2次)4天之后,在24小时内频繁采集血液和尿液样本。西咪替丁使氨苯蝶啶经羟基化作用后的清除率显著降低了32%(P<0.016),使氨苯蝶啶的CLR降低了28%(P<0.063),而其蛋白结合率未发生变化。西咪替丁未改变氨苯蝶啶活性硫酸结合物的CLR。给予西咪替丁后,氨苯蝶啶及其代谢产物在尿液中的回收率降低,提示吸收减少。这些结果与西咪替丁抑制肝脏中的细胞色素P-450酶以及与氨苯蝶啶竞争肾小管分泌作用相符。尽管存在药代动力学相互作用,但西咪替丁对氨苯蝶啶的利钠和抗利尿作用影响极小。